| Glucocerebrosidase activity modulates neuronal susceptibility to pathological α-synuclein insult MX Henderson, S Sedor, I McGeary, EJ Cornblath, C Peng, DM Riddle, ... Neuron 105 (5), 822-836. e7, 2020 | 126 | 2020 |
| Computational modeling of tau pathology spread reveals patterns of regional vulnerability and the impact of a genetic risk factor EJ Cornblath, HL Li, L Changolkar, B Zhang, HJ Brown, RJ Gathagan, ... Science advances 7 (24), eabg6677, 2021 | 40 | 2021 |
| Unlocked yet untapped: the ubiquitous smartphone and utilization of emergency medical identification technology in the care of the injured patient MA Vella, H Li, PM Reilly, SS Raza Surgery Open Science 2 (3), 122-126, 2020 | 5 | 2020 |
| LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression N Lubben, JK Brynildsen, CM Webb, HL Li, CEG Leyns, L Changolkar, ... Translational Neurodegeneration 13 (1), 13, 2024 | 4 | 2024 |
| Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signatures CJ Kao, S Charmsaz, SL Alden, M Brancati, HL Li, A Balaji, K Munjal, ... The Journal of Clinical Investigation 134 (20), 2024 | 2 | 2024 |
| Incidence, risk factors, and outcomes of immune-related adverse events (irAEs) in a prospective, pan-tumor population. A Balaji, SL Alden, H Li, K Munjal, EJ Lipson, J Naidoo, L Cappelli, Y Ged, ... Journal of Clinical Oncology 41 (16_suppl), 2662-2662, 2023 | 2 | 2023 |
| Tau pathology spreads between anatomically-connected regions of the brain and is modulated by a LRRK2 mutation MX Henderson, EJ Cornblath, HL Li, L Changolkar, B Zhang, HJ Brown, ... bioRxiv, 2020.10. 13.337857, 2020 | 2 | 2020 |
| Investigating peripheral blood biomarkers of immune checkpoint inhibitor associated fatigue. HL Li, S Charmsaz, SL Alden, M Brancati, A Warner, K Munjal, HL Tsai, ... Journal of Clinical Oncology 42 (16_suppl), 2571-2571, 2024 | | 2024 |
| Survival outcomes and molecular drivers of testicular cancer in hispanic men ME Rezaee, R Elias, HL Li, P Agrawal, M Pallauf, D Enikeev, Y Ged, ... Urologic Oncology: Seminars and Original Investigations, 2024 | | 2024 |
| The obesity paradox in immune checkpoint blockade: A pan-tumor analysis SL Alden, S Charmsaz, M Brancati, HL Li, A Warner, K Munjal, K Howe, ... Cancer Research 84 (6_Supplement), 3846-3846, 2024 | | 2024 |
| 1245 Th17 and Type 2 CD8+ cytokine signatures predict irAEs in solid tumors CJ Kao, S Charmsaz, M Brancati, SL Alden, HL Li, A Balaji, K Munjal, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology spread N Lubben, JK Brynildsen, CM Webb, HL Li, CEG Leyns, L Changolkar, ... bioRxiv, 2023.10. 06.561190, 2023 | | 2023 |
| Computational modeling of tau pathology spread reveals genetic correlates of regional vulnerability and the impact of a LRRK2 mutation (P9-3.005) E Cornblath, H Li, L Changolkar, B Zhang, H Brown, R Gathagan, ... Neurology 98 (18_supplement), 567, 2022 | | 2022 |
